Selective inhibition of the JAK2/STAT3 axis, an IFN-γ, IL-6 and IL-23 receptor signaling response element, by Pacritinib (SB1518) was also shown to significantly reduce GVHD in murine models (181, 225). The gene discussed is IL6; the disease is graft versus host disease.